The sex-stratified data inside them is more interesting
Yes, clinical trials suggest that Mounjaro (tirzepatide) can lead to greater weight loss compared to other GLP-1 medications like semaglutide (Wegovy) or liraglutide (Saxenda), particularly due to its dual action on GLP-1 and GIP receptors.
While the parent trials primary outcomes were changes in adipose tissue volume (measured by CT) and body composition (DXA scans) at 32 weeks, our current analysis focuses on epigenetic aging markers as secondary/exploratory outcomes
[3] Meyre, D., Mohamed, S., Gray, J.C
She says K Health, for example, has strict criteria for prescribing GLP-1 agonist medications to ensure theyre only going to patients who really need them
North America leads